Skip to main content

Table 2 Baseline patient demographic and clinical characteristics

From: Assessment of strategies for switching patients from olanzapine to risperidone: A randomized, open-label, rater-blinded study

 

Abrupt (n= 37)

Gradual 1 (n= 39)

Gradual 2 (n= 40)

Sex, % female

51

51

50

Race/ethnicity, %

   

   White

57

54

53

   Black

32

31

33

   Hispanic

5

13

8

   Asian

5

3

5

Age, mean (± SD) years

41.6 (± 10.2)

41.5 (± 10.4)

40.3 (± 9.1)

BMI, mean (± SD) kg/m2

36.2 (± 9.1)

34.0 (± 6.2)

32.3 (± 4.7)

Diagnosis, %

   

   Schizophrenia

57

56

53

   Schizoaffective disorder

43

44

47

Olanzapine dose, mean (± SD) mg/day

14.4 (± 5.4)

15.5 (± 6.3)

16.4 (± 7.9)